Back to search
Publication

Long-term persistence of anti-β2 glycoprotein I in treated leprosy patients.

Abstract

β2 glycoprotein I (β2GPI) is a phospholipid binding protein that plays an important role in endothelial stability, blood coagulation, clearance of apoptotic debris and other physiologic processes. Anti-β2GPI antibodies occur in normal individuals and transiently during the course of infections, but are also associated with thrombotic events in autoimmune disease: the antiphospholipid syndrome (APS). A total of 31 out of 37 treated leprosy patients previously found to present high titers of IgM anti-β2GPI and/or anticardiolipin antibodies (aCL) remained positive for IgM antiphospholipid antibodies (aPL), and exhibited high titers of anti-β2GPI. The 37 patients were part of the 77 aPL-positive patients from a previous study that evaluated 158 leprosy patients. The median time elapsed between the first and second sample was 66 months. None of the 37 patients had any thrombotic event and 24 had a reactional state and were still requiring the use of prednisone, thalidomide or both. None of them fulfilled World Health Organization criteria for leprosy recurrence.

More information

Type
Journal Article
Author
Ribeiro S
Pereira H
Silva N
Sato E
Passos L
Dos-Santos M
Keywords
Year of Publication
2014
Journal
Lupus
Volume
23
Issue
12
Number of Pages
1249-51
Language
eng
ISSN Number
1477-0962
DOI
10.1177/0961203314529469
Short Title
Lupus
Alternate Journal
Lupus
Publication Language
eng